Context: An increased cancer mortality is reported in transplanted patients. Objective: This multicentric study aimed to investigate the rate of thyroid cancer recurrence after transplantation. Results: Sixty-eight patients (35 male/33 female) with a history of both thyroid cancer and organ transplantation were recruited via two nationwide French networks. Histological analysis identified 58 papillary (88%), 5 follicular (7.5%), and 3 poorly differentiated cancer cases (4.5 %). Thirty-one patients (52%) presented high recurrence risk tumors. In the 36 patients with thyroid cancer diagnosed after transplantation, the 5-year disease-free survival (DFS) was 74.7% (SE: 7.3%). One patient died after progression of a poorly differentiated cancer. Persistent disease was observed in six high-risk patients. One of them underwent a second transplantation and disease remained stable after 5 years of follow-up. Thyroid cancer had been diagnosed before transplantation in 32 patients. One patient with cystic fibrosis and thyroid lung metastases at the time of lung transplantation underwent a 4-year remission. For the 31 patients in remission at thetime of transplantation, the 5-year DFS was 93.1% (SE:4.8%). Two patients with local recurrence presented subsequent remission. For the entire study population, the 5-year and 9-year DFS were 81.9% (SE: 5.5%) and 75.6% (SE: 7.9%), respectively. Recurrence or persistent disease occurred in patients with high-risk tumors. Conclusions: The prognosis of thyroid cancer does not seem to be altered by transplantation. This suggests that a history of thyroid cancer should not be considered a contraindication. Copyright © 2013 by The Endocrine Society.
CITATION STYLE
Tisset, H., Kamar, N., Faugeron, I., Roy, P., Pouteil-Noble, C., Klein, M., … Borson-Chazot, F. (2013). Is thyroid cancer recurrence risk increased after transplantation? Journal of Clinical Endocrinology and Metabolism, 98(10), 3981–3988. https://doi.org/10.1210/jc.2013-1357
Mendeley helps you to discover research relevant for your work.